Dynamics of tumour hypoxia and metabolism during Chemoradiotherapy for stage III Non Small Cell Lung Cancer, using 18F-FAZA-PET/CT and 18F-FDG-PET/CT. A Pilot Study

Dynamics of tumour hypoxia and metabolism during Chemoradiotherapy for stage III Non Small Cell Lung Cancer, using 18F-FAZA-PET/CT and 18F-FDG-PET/CT. A Pilot Study - Tumour hypoxia and tumour metabolism during Chemoradiotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39397

Enrollment

Registered

2010-12-17

Start date

2011-03-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small-cell-lung-cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - WHO PS 0-2 - Histological or cytological confirmation of non-small cell lung cancer. - Stage IIIA or IIIB - Adequate pulmonary function estimated by flow volume curves - Life expectancy of at least 6 months - Planned for 25 x 2.4 Gy 3DCRT, with concomitant chemotherapy

Exclusion criteria

Exclusion criteria: - Other stages than stage III NSCLC - PS > 2

Design outcomes

Primary

Measure	Time frame
Assessing tumour hypoxia using 18F-FAZA-PET/CT for stage III NSCLC during curative chemoradiotherapy	—

Secondary

Measure	Time frame
To investigate tumour heterogeneity with respect to metabolism (18F-FDG-PET) and hypoxia (18F-FAZA-PET) Correlation between 18F-FAZA-PET/CT identified tumour hypoxic areas and 18F-FDG-PET/CT metabolically active areas To investigate metabolic response as assessed by 18F-FDG-PET/CT during treatment To investigate hypoxia response as assessed by 18F-FAZA-PET/CT during treatment	—

Countries

Netherlands

Outcome results